![]() Several risk scores have been developed to predict CVD both in the general population and specifically in patients with T2DM. However, prospective studies assessing the prognostic value of aortic pulse wave velocity (aPWV), a marker of arterial stiffness, in subjects with T1DM are lacking. Arterial stiffness predicts cardiovascular events independently of classical cardiovascular risk factors in several populations, and its estimation has been demonstrated to improve cardiovascular risk prediction beyond the Framingham Risk Score. Īrterial stiffness is an early indicator of arteriosclerosis and vascular damage and, accordingly, it´s analysis could provide insights into arteriosclerotic mechanisms long before any cardiovascular event occurs. Moreover, T1DM causes a life expectancy loss of about 11 years for men and 13 years for women, with the largest percentage of the estimated loss in life expectancy related to ischemic heart disease (up to one-third). Indeed, the relative risk of death from CAD in T1DM can be ten times greater than that in the non-diabetic population, especially in women, and it is even greater than the relative risk in type 2 diabetes (T2DM). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.Ĭompeting interests: The authors have declared that no competing interests exist.Ĭardiovascular disease (CVD) is the leading cause of death in patients with type 1 diabetes mellitus (T1DM), with coronary artery disease (CAD) as the principal manifestation. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript and its Supporting Information files.įunding: Financial support was provided through the Fondo de Investigación Sanitaria (FIS) PI09/01360 (PI: JMCG), PI12/00954 (PI: JMCG) and PI15/00567 (PI: JMCG) as part of the National R+D+I (2008-2011) and was co-financed by the Instituto de Salud Carlos III - General Evaluation Branch (Spanish Ministry of Economy and Competitiveness) and the European Regional Development Fund (ERDF). Received: MaAccepted: JPublished: September 4, 2019Ĭopyright: © 2019 Llauradó et al. PLoS ONE 14(9):Įditor: Petter Bjornstad, University of Colorado Denver School of Medicine, UNITED STATES (2019) Arterial stiffness is highly correlated with the scores obtained from the Steno Type 1 Risk Engine in subjects with T1DM. I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Citation: Llauradó G, Cano A, Albert L, Ballesta S, Mazarico I, Luchtenberg M-F, et al. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). ![]() I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. This project was approved by the IRB of the Quebec Heart and Lung Institute.Īll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. The details of the IRB/oversight body that provided approval or exemption for the research described are given below:Īnalyses performed with the UK Biobank dataset were conducted under UK Biobank data application number 25205. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. This work was supported by a grant from the Canadian Institutes of Health Research (PJT-162344) to ST. PM holds a FRQS Research Chair on the Pathobiology of Calcific Aortic Valve Disease. ![]() ![]() YB holds a Canada Research Chair in Genomics of Heart and Lung Diseases. Funding StatementīJA and ST hold junior scholar awards from the FRQS. PM is a consultant for Casebia Therapeutics. Competing Interest StatementīJA is a consultant for Novartis and Silence Therapeutics and has received research funding from Pfizer and Ionis Pharmaceuticals. PRS could optimize the identification and management of individuals at risk for CAD. Conclusion Our PRS CAD predicts MI incidence and all-cause mortality, especially in men aged between 40-51 years. ![]()
0 Comments
Leave a Reply. |